4 min read
As the Australian market rebounds, with the ASX showing positive momentum and gold reaching new highs, investors are keenly observing opportunities across various sectors. Penny stocks, though an old term, continue to capture attention as they often represent smaller or newer companies that can offer growth potential at lower price points. By focusing on those with strong financials and a clear growth trajectory, these stocks can present valuable opportunities for investors seeking to explore underappreciated segments of the market.
|
Name |
Share Price |
Market Cap |
Financial Health Rating |
|
Alfabs Australia (ASX:AAL) |
A$0.485 |
A$139M |
★★★★★☆ |
|
EZZ Life Science Holdings (ASX:EZZ) |
A$2.53 |
A$119.35M |
★★★★★★ |
|
Dusk Group (ASX:DSK) |
A$0.83 |
A$51.68M |
★★★★★★ |
|
IVE Group (ASX:IGL) |
A$2.72 |
A$418.78M |
★★★★★☆ |
|
MotorCycle Holdings (ASX:MTO) |
A$3.30 |
A$243.56M |
★★★★★★ |
|
Pureprofile (ASX:PPL) |
A$0.044 |
A$51.47M |
★★★★★★ |
|
Veris (ASX:VRS) |
A$0.071 |
A$37.4M |
★★★★★★ |
|
West African Resources (ASX:WAF) |
A$3.04 |
A$3.47B |
★★★★★★ |
|
Praemium (ASX:PPS) |
A$0.75 |
A$358.29M |
★★★★★★ |
|
Service Stream (ASX:SSM) |
A$2.28 |
A$1.4B |
★★★★★★ |
Click here to see the full list of 423 stocks from our ASX Penny Stocks screener.
Let’s dive into some prime choices out of the screener.
Simply Wall St Financial Health Rating: ★★★★☆☆
Overview: Australian Clinical Labs Limited offers pathology diagnostic services in Australia and has a market cap of A$482.28 million.
Operations: The company’s revenue primarily comes from its Pathology/Clinical Laboratory Services segment, which generated A$741.27 million.
Market Cap: A$482.28M
Australian Clinical Labs Limited, with a market cap of A$482.28 million, reported significant earnings growth of 35.5% over the past year, surpassing its five-year average decline. Its net profit margins improved to 4.4%, and interest payments are well-covered by EBIT at 4.8 times coverage. The company completed a share buyback program and is exploring accretive acquisitions for growth. Despite trading below estimated fair value and having satisfactory debt levels, short-term assets do not cover liabilities, posing a risk factor. The management team is experienced with an average tenure of 6.3 years, supporting operational stability amidst strategic expansion efforts.
Simply Wall St Financial Health Rating: ★★★★★★
Overview: Delta Lithium Limited focuses on the exploration and development of lithium properties in Western Australia, with a market cap of A$136.27 million.
